Results 221 to 230 of about 81,753 (307)

HDAC Inhibitor CHR-2845 [PDF]

, 2020
openaire   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites. [PDF]

J Enzyme Inhib Med Chem
Mathew J, Mishra A, Le TN, Liou JP, Lai MJ, Rao Neralla V.   +5 more
europepmc   +1 more source

HDAC Inhibitor AR-42 [PDF]

, 2020
openaire   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells. [PDF]

Cancers (Basel)
Bhutkar S, Yadav A, Patel H, Barot S, Patel K, Dukhande VV.   +5 more
europepmc   +1 more source

Polygonum cognatum Extract: Multitarget Anti‐inflammatory, Antidiabetic, and Epigenetic Modulation Properties

ChemistryOpen, Volume 15, Issue 2, February 2026.
Polygonum cognatum extracts exhibit strong antioxidant, anti‐inflammatory, antidiabetic, and antimicrobial activities. This study demonstrates, for the first time, histone deacetylase inhibitory activity, revealing epigenetic modulation potential.
Serhat Karaman, Yakup Budak, Elif Aktürk Bozdemir   +2 more
wiley   +1 more source

Design and radiosynthesis of class-IIa HDAC inhibitor with high molar activity via repositioning the ¹⁸F-radiolabel. [PDF]

Sci Rep
Xu S, Huang CH, Eyermann C, Georgakis GV, Turkman N.   +4 more
europepmc   +1 more source

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source